MAIA Biotechnology closed at $1.14 on Nov 4, up 5.56%, 61.4% below its 52-week closing high. Volume of 267.4K shares was 0.87× its 20-day average (close to normal).
Split-adjusted performance: -4.2% over one month, -15.6% over six months, -1.7% over one year.
Short interest was 2.5M shares at the Oct 15 settlement, down 6.2% from the prior report (6.0% of float, 5.8 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MAIAMAIA Biotechnology | $1.14 | +5.56% | −15.6% | — | — | — | $70.4M | |
| PMVPPMV Pharmaceuticals | $1.33 | −3.99% | −8.6% | — | — | — | $70.8M | Compare |
| MNOVMedicinova | $1.45 | +2.11% | 0.0% | +240.6% | −504.8% | — | $71.4M | Compare |
| CRBPCorbus Pharmaceuticals Holdings | $3.57 | −7.75% | −67.3% | — | — | — | $69.0M | Compare |
| COYACoya Therapeutics | $3.08 | −0.96% | −27.4% | +49.0% | −2723.4% | — | $72.3M | Compare |
| TENXTenax Therapeutics | $1.81 | −1.63% | −84.9% | — | — | — | $67.7M | Compare |
| CPIXCumberland Pharmaceuticals | $4.44 | +3.02% | +1.6% | −56.3% | −2569.0% | — | $66.5M | Compare |
| ACRVAcrivon Therapeutics | $1.74 | +4.19% | −16.7% | — | — | — | $74.6M | Compare |
| CINGCingulate | $4.56 | −3.39% | −14.4% | — | — | — | $66.3M | Compare |
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
